New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
09:00 EDTBIIBBiogen May volatility elevated at 43 into Q1 and revenue outlook
Biogen May call option implied volatility is at 43, July and October is at 38; compared to its 26-week average of 348according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 23.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
07:14 EDTBIIBBiogen volatility flat into new drug data
Biogen overall option implied volatility of 35 compares to its 26-week average of 34 according to Track Data, suggesting non-directional into results as shares rally in the preopen on Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis clinical data.
April 14, 2015
18:30 EDTBIIBOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTBIIBBiogen presents new Anti-LINGO-1 Phase 2 AON data
Subscribe for More Information
11:25 EDTBIIBPTAB declares interference between Forward Pharma and Biogen regarding treatment
Subscribe for More Information
April 9, 2015
09:25 EDTBIIBPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
07:27 EDTBIIBBiogen PML death case previously reported, says Deutsche Bank
Subscribe for More Information
07:23 EDTBIIBDoctors report case of fatal PML in patient treated with Tecfidera to NEJM
Subscribe for More Information
April 8, 2015
07:24 EDTBIIBNeurotechnology Industry Organization to hold a conference
Subscribe for More Information
April 7, 2015
07:31 EDTBIIBBiogen to present data on neurological disease therapies at AAN meeting
Subscribe for More Information
07:14 EDTBIIBEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use